LiverLearning®: 2018 Webinar: Surgical Risk in the Portal Hypertensive Patient

The webinar will focus on the best practices and the underlying evidence in terms of surgical management of the portal hypertensive patient. A practical approach will be outlined whereby patient risk, assessment, and management will be discussed. This is an essential and daily part  of practice for hepatologists and this  webinar will update and educate as to current management.Brett E. Fortune (Moderator) Brett E. Fortune, MD, MSc, is a transplant hepatologist who works at New York Presbyterian/Weill Cornell for the Center for Liver Disease and Transplantation. Dr.

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment

Margo J.H. van Campenhout, Florian van Bömmel, Maria Pfefferkorn, Janett Fischer, Danilo Deichsel, André Boonstra, Anneke J. van Vuuren, Thomas Berg, Bettina E. Hansen, Harry L.A. Janssen – 7 March 2018 – Hepatitis B virus (HBV) RNA in serum is a novel biomarker for intrahepatic HBV replication and treatment response. For its proper use, it is essential to identify factors influencing serum HBV RNA level.

Liver transplantation for intrahepatic cholangiocarcinoma

David D. Lee, Kristopher P. Croome, Kaitlyn R. Musto, Jose Melendez, Ghassan Tranesh, Raouf Nakhleh, C. Burcin Taner, Justin H. Nguyen, Tushar Patel, Denise M. Harnois – 7 March 2018 – Although hepatocellular carcinoma (HCC) has become a common indication for liver transplantation (LT), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular carcinoma–cholangiocarcinoma (cHCC‐CCA) are historically contraindicated due to their aggressive behavior.

Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis

Annie J. Kruger, Bryan C. Fuchs, Ricard Masia, Jacinta A. Holmes, Shadi Salloum, Mozhdeh Sojoodi, Diego S. Ferreira, Stephanie M. Rutledge, Peter Caravan, Nadia Alatrakchi, Pam Vig, Eric Lefebvre, Raymond T. Chung – 7 March 2018 – Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver transplantation in the next decade. Cenicriviroc (CVC), a dual chemokine receptor 2 and 5 antagonist, prevents macrophage trafficking and is under clinical investigation for the treatment of human NASH fibrosis.

A single blood test adjusted for different liver fibrosis targets improves fibrosis staging and especially cirrhosis diagnosis

Paul Calès, Jérôme Boursier, Frédéric Oberti, Valérie Moal, Isabelle Fouchard Hubert, Sandrine Bertrais, Gilles Hunault, Marie Christine Rousselet, multicentric groups (SNIFF, ANRS HC 23) – 5 March 2018 – Fibrosis blood tests are usually developed using significant fibrosis, which is a unique diagnostic target; however, these tests are employed for other diagnostic targets, such as cirrhosis. We aimed to improve fibrosis staging accuracy by simultaneously targeting biomarkers for several diagnostic targets.

Subscribe to